Profile data is unavailable for this security.
About the company
Cyfuse Biomedical KK is a Japan-based company mainly engaged in the research, development, manufacture and sale of cell products. The Company is engaged in the development of pipelines for obtaining approval for regenerative medicine products and contract research cell products in the field of regenerative medicine. The Company is engaged in the development of cell products as tools for drug discovery support for pharmaceutical companies in the drug discovery support field. The Company is engaged in the development and sell of three-dimensional cell stacking system equipment equipped with basic technology, apply technology for cell product development, and develop new technology in the device field.
- Revenue in JPY (TTM)57.69m
- Net income in JPY-718.81m
- Incorporated2010
- Employees21.00
- LocationCyfuse Biomedical KK5A, ICN Bldg., 2-27-17, HongoMINATO-KU 108-6301JapanJPN
- Phone+81 364351885
- Fax+81 364351883
- Websitehttps://www.cyfusebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PhoenixBio Co Ltd | 1.62bn | -126.00m | 1.47bn | 70.00 | -- | 0.8701 | -- | 0.9056 | -31.31 | -31.31 | 408.76 | 416.03 | 0.5679 | 1.05 | 5.81 | 23,168,070.00 | -4.41 | -4.04 | -6.32 | -5.28 | 72.27 | 65.88 | -7.77 | -6.97 | 3.65 | -1.07 | 0.207 | -- | -19.24 | 6.91 | -94.65 | -- | -9.96 | -- |
| Ribomic Inc | 2.11m | -949.28m | 3.30bn | 24.00 | -- | 1.00 | -- | 1,564.81 | -25.76 | -25.76 | 0.057 | 80.86 | 0.0006 | -- | 0.0677 | 87,791.66 | -25.76 | -30.52 | -26.68 | -31.71 | -- | -- | -45,053.58 | -1,777.84 | 30.87 | -- | 0.00 | -- | -100.00 | -- | 38.04 | -- | 4.42 | -- |
| Human Metabolome Technologies Inc | 1.38bn | 246.02m | 3.58bn | 58.00 | 14.52 | 1.97 | 10.24 | 2.58 | 41.59 | 41.59 | 234.08 | 306.43 | 0.6291 | 8.87 | 7.76 | 23,872,380.00 | 11.18 | 8.49 | 14.00 | 10.80 | 65.13 | 69.25 | 17.77 | 13.21 | 3.73 | 33.22 | 0.1088 | 18.31 | 3.57 | -- | -14.88 | -- | -- | -- |
| Cyfuse Biomedical KK | 57.69m | -718.81m | 3.68bn | 21.00 | -- | 1.35 | -- | 63.72 | -89.81 | -89.81 | 7.24 | 335.21 | 0.0147 | 0.5261 | 40.19 | 2,747,238.00 | -18.36 | -- | -21.62 | -- | 55.40 | -- | -1,245.95 | -- | 5.52 | -91.45 | 0.2268 | -- | -83.68 | -- | -24.32 | -- | -- | -- |
| D.Western Therapeutics Institute Inc | 464.18m | -1.09bn | 4.25bn | 21.00 | -- | 4.34 | -- | 9.16 | -33.74 | -33.74 | 14.43 | 25.80 | 0.19 | 0.3314 | 4.10 | 22,103,620.00 | -44.77 | -13.06 | -47.81 | -14.36 | 91.27 | 94.29 | -235.62 | -72.51 | 18.24 | -- | 0.5644 | -- | -4.40 | 7.90 | -89.07 | -- | 7.08 | -- |
| BrightPath Biotherapeutics Co Ltd | 84.00k | -1.15bn | 4.26bn | 24.00 | -- | 3.39 | -- | 50,768.63 | -16.73 | -16.73 | 0.0012 | 14.73 | 0.00006 | -- | 2.80 | 3,500.00 | -80.63 | -51.56 | -97.29 | -54.32 | 75.00 | 68.63 | -1,372,495.00 | -22,321.82 | -- | -- | 0.2085 | -- | -98.64 | -78.47 | 21.37 | -- | -46.55 | -- |
| FunPep Co Ltd | 530.00k | -727.29m | 4.41bn | 15.00 | -- | 1.65 | -- | 8,316.22 | -29.40 | -29.40 | 0.0215 | 82.55 | 0.0002 | -- | -- | 35,333.33 | -26.27 | -27.10 | -29.12 | -28.75 | -- | -- | -137,223.40 | -815.82 | 5.06 | -1,004.01 | 0.00 | -- | -50.33 | -72.80 | 20.39 | -- | -13.14 | -- |
| Kidswell Bio Corp | 3.60bn | -883.62m | 4.63bn | 42.00 | -- | 5.41 | -- | 1.29 | -22.78 | -22.78 | 92.26 | 21.08 | 0.9182 | 2.73 | 6.63 | 85,697,070.00 | -22.54 | -57.41 | -35.96 | -81.13 | 36.17 | 55.20 | -24.55 | -123.52 | 1.64 | -17.95 | 0.7132 | -- | -12.43 | 18.93 | -116.31 | -- | -- | -- |
| DNA Chip Research Inc | 766.32m | -118.13m | 4.73bn | 37.00 | -- | 6.74 | -- | 6.17 | -18.29 | -18.29 | 116.80 | 103.64 | 0.9159 | 8.50 | 7.86 | 20,711,350.00 | -14.12 | -23.49 | -17.74 | -26.70 | 38.52 | 14.28 | -15.41 | -54.10 | 2.78 | -641.51 | 0.00 | -- | 49.74 | 6.33 | 31.48 | -- | -15.75 | -- |
Data as of Nov 22 2024. Currency figures normalised to Cyfuse Biomedical KK's reporting currency: Japanese Yen JPY
0.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nippon Life Insurance Co. (Investment Portfolio)as of 15 Mar 2023 | 38.00k | 0.47% |
| Asset Management One Co., Ltd.as of 07 Dec 2023 | 1.00k | 0.01% |
| Fivestar Asset Management Co. Ltd.as of 27 Feb 2024 | 0.00 | 0.00% |
Data from 25 Apr 2024 - 01 Nov 2024Source: FactSet Research Systems Inc.
